Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371475 | 1.00 | GABRR1 (0.48) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL2370535 | 1.00 | GABRR1 (0.48) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL2371471 | 1.00 | GABRR1 (0.48) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL9112735 | 1.00 | GABRR1 (0.48) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL19526286 | 1.00 | GABRR1 (0.48) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL28046282 | 0.87 | GABRR1 (0.44) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL14821724 | 0.87 | GABRR1 (0.39) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL12855800 | 0.87 | MEN1 (0.39) | GABRR1ALDH1A1LMNAPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL9114749 | 0.82 | GABRR1 (0.50) | GABRR1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL7280473 | 0.82 | POLB (0.39) | GABRR1ALDH1A1LMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4499634-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-2121674-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARM LTD (IE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2121674-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARM LTD (IE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| WO-2010010079-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
| EP-2147684-A1 | Diagnostic Agents Selective Against Metalloproteases | Bracco Imaging S.p.A (IT) | 2010-01-27 | — | — | EP | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| WO-2008092955-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| WO-1995007022-A1 | FUNGICIDES | ZENECA LIMITED (GB) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | PREP, SPINT2, PEPD | GABRR1 4457/4885ALDH1A1 1899/4885LMNA 2912/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | GABRR1 4540/4885ALDH1A1 3620/4885LMNA 2004/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | GABRR1 4540/4885ALDH1A1 3620/4885LMNA 2004/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | GABRR1 685/4885ALDH1A1 3450/4885LMNA 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.